Ticker >

Themis Medicare share price

Themis Medicare Ltd.

NSE: THEMISMED BSE: 530199 SECTOR: Pharmaceuticals & Drugs  33k   63   6

264.75
+1.65 (0.63%)
BSE: 04 Nov 03:31 PM

Price Summary

Today's High

₹ 266.2

Today's Low

₹ 254

52 Week High

₹ 304.3

52 Week Low

₹ 142.6

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

2436.76 Cr.

Enterprise Value

2513.35 Cr.

No. of Shares

9.2 Cr.

P/E

66.6

P/B

7.49

Face Value

₹ 1

Div. Yield

0.19 %

Book Value (TTM)

₹  35.33

CASH

19.2 Cr.

DEBT

95.79 Cr.

Promoter Holding

67.15 %

EPS (TTM)

₹  3.98

Sales Growth

7.74%

ROE

8.49 %

ROCE

11.43%

Profit Growth

-42.84 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year7.74%
3 Year18.29%
5 Year15.7%

Profit Growth

1 Year-42.84%
3 Year-2.4%
5 Year31.61%

ROE%

1 Year8.49%
3 Year17.9%
5 Year15.94%

ROCE %

1 Year11.43%
3 Year20.79%
5 Year18.42%

Debt/Equity

0.318

Price to Cash Flow

110.54

Interest Cover Ratio

4.6974

CFO/PAT (5 Yr. Avg.)

0.754181969862629

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2024 67.15 2.43
Jun 2024 67.15 2.43
Mar 2024 67.15 2.43
Dec 2023 67.16 2.43
Sep 2023 67.16 23.51
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good revenue growth of 18.2858518007061% for the Past 3 years.
  • Company has been maintaining healthy ROCE of 20.7925666666667% over the past 3 years.
  • The company has an efficient Cash Conversion Cycle of 83.3534 days.
  • The company has a high promoter holding of 67.15%.

 Limitations

  • The company has shown a poor profit growth of -2.40309736886984% for the Past 3 years.
  • The company is trading at a high PE of 66.6.
  • The company is trading at a high EV/EBITDA of 36.9103.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
Net Sales 73.55 82.51 97.82 106.08 99.59
Total Expenditure 70.29 74.45 88.5 76.83 82.57
Operating Profit 3.26 8.07 9.32 29.25 17.02
Other Income 2.24 0.57 1.1 0.71 0.77
Interest 1.74 2.69 2.16 1.44 1.6
Depreciation 1.1 3.1 3.06 1.01 1.06
Exceptional Items 0 0 0 0 0
Profit Before Tax 2.66 2.85 5.2 27.51 15.13
Tax 0.86 0.85 2.11 7.2 3.95
Profit After Tax 1.8 2 3.09 20.31 11.19
Adjusted EPS (Rs) 0.2 0.22 0.34 2.21 1.22

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 201.59 230.67 394.61 354.32 381.76
Total Expenditure 165.91 180.79 298.96 286.86 330.23
Operating Profit 35.68 49.88 95.65 67.46 51.53
Other Income 3.47 3.62 6.54 11.5 4.76
Interest 12.88 12.71 8.77 9.56 9.38
Depreciation 8.27 8.55 9.48 10.49 12.25
Exceptional Items 0 0 0 0 0
Profit Before Tax 18.01 32.25 83.94 58.91 34.67
Tax 2.09 5.63 22.38 15.61 9.92
Net Profit 15.91 26.62 61.56 43.29 24.75
Adjusted EPS (Rs.) 1.73 2.9 6.69 4.7 2.69

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 9.19 9.19 9.2 9.2 9.2
Total Reserves 150.13 176.61 234.28 272.62 292.07
Borrowings 11.85 22.2 23.88 28.45 26.77
Other N/C liabilities -4.35 2.13 6.89 6.94 7.39
Current liabilities 154.79 128.27 123.48 149.32 163.82
Total Liabilities 321.61 338.4 397.74 466.54 499.27
Assets
Net Block 116.31 133.1 144 162.2 168.36
Capital WIP 7.54 2.47 2.56 2.6 2.6
Intangible WIP 0 0 0 0 0
Investments 10.96 10.98 11.01 11.07 11.17
Loans & Advances 2.91 2.83 6.9 12.81 12.46
Other N/C Assets 2.62 2.31 3.84 1.82 0.93
Current Assets 181.28 186.72 229.42 276.05 303.74
Total Assets 321.61 338.4 397.74 466.54 499.27
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 18.01 32.25 83.94 58.91 34.67
Adjustment 18.22 17.13 11.1 13.66 17.32
Changes in Assets & Liabilities -35.65 7.52 -42.57 -40.34 -20.99
Tax Paid -0.24 0.08 -18.07 -16.15 -8.96
Operating Cash Flow 0.33 56.98 34.39 16.07 22.04
Investing Cash Flow -5.46 -15.65 -15.58 -23.96 -15.96
Financing Cash Flow 6.72 -25.65 -17.55 0.14 -8.77
Net Cash Flow 1.6 15.68 1.26 -7.75 -2.68

Corporate Actions

Investors Details

PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
promoters 67.16 67.16 67.15 67.15 67.15
anay rupen choksi 1.28 1.28 1.28 1.28 1.28
dinesh s patel huf 1.07 1.07 1.07 - 1.07
dinesh shantilal patel 9.48 9.48 9.47 9.47 9.47
gedeon richter investment... 9.61 9.61 9.61 9.61 9.61
jayshree d patel 7.26 7.26 7.25 7.25 7.25
nysha rupen choksi 1.28 1.28 1.28 1.28 1.28
reena s patel 4.04 4.04 4.04 4.04 4.04
sachin dinesh patel 5.99 5.99 5.99 5.99 5.99
shantilal dahyabhai patel... - - - 0.61 0.61
themis distributors priva... - - - - 2.98
vividh distributors pvt l... - - - - 7.78
vividhmargi investments p... 15.79 15.79 15.78 - 15.78
dinesh s patel (huf) - - - 1.07 -
themis distributors priva... 2.98 2.98 2.98 2.98 -
vividh distributors priva... 7.78 7.78 7.78 7.78 -
vividhmargi investments p... - - - 15.78 -
shantilal dahyabhai patel... 0.61 0.61 0.61 - -
gedeon richter investment... 9.61 9.61 9.61 9.61 9.61
PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
investors 32.84 32.84 32.85 32.85 32.85
anuj anantrai sheth 4.89 4.89 4.89 4.89 4.85
investor education and pr... 0.34 - 0.34 0.34 0.34
jagat navratna lodha - - 1.32 1.32 1.32
llp 0.66 0.40 0.40 0.34 0.25
za capital services india... 1.61 1.61 1.59 1.58 1.53
zafar ahmadullah 2.34 - - 2.34 2.34
zafar ahmadullah - 2.34 2.34 - -
investor education and pr... - 0.34 - - -
jagat lodha 1.30 1.30 - - -
jewels advisory services ... 1.35 1.23 - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Themis Medicare - Quaterly Results25 Oct 2024, 7:05PM Themis Medicare - Quaterly Results25 Oct 2024, 7:05PM Gujarat Biosyn Themis informs about voting results & scrutinizer’s report 15 Oct 2024, 12:56PM Themis Medicare - Quaterly Results26 Jul 2024, 7:10PM Themis Medicare - Quaterly Results26 Jul 2024, 7:10PM Themis Medicare - Quaterly Results26 Jul 2024, 7:10PM Themis Medicare informs about newspaper advertisement17 May 2024, 12:05PM Themis Medicare informs about investors presentation15 May 2024, 10:12AM Themis Medicare - Quaterly Results14 May 2024, 9:45PM Themis Medicare - Quaterly Results14 May 2024, 9:45PM Themis Medicare informs about compliance certificate16 Apr 2024, 10:56AM Themis Medicare informs about certificate8 Apr 2024, 11:48AM Themis Medicare informs about newspaper publication 12 Mar 2024, 11:03AM Themis Medicare - Quaterly Results10 Feb 2024, 2:47PM Themis Medicare - Quaterly Results10 Feb 2024, 2:47PM Themis Medicare - Quaterly Results10 Feb 2024, 2:47PM Themis Medicare launches novel Opioid Injectable Analgesic ‘Remifentanil’10 Nov 2023, 3:42PM Themis Medicare informs about newspaper publication6 Nov 2023, 4:10PM Themis Medicare - Quaterly Results4 Nov 2023, 2:36PM Themis Medicare - Quaterly Results4 Nov 2023, 2:36PM Themis Medicare - Quaterly Results4 Nov 2023, 2:36PM Themis Medicare informs about newspaper publication17 Oct 2023, 12:20PM Themis Medicare informs about certificate 9 Oct 2023, 11:17AM Themis Medicare informs about closure of trading window28 Sep 2023, 12:51PM Themis Medicare incorporates wholly owned subsidiary20 Sep 2023, 2:22PM Themis Medicare - Quaterly Results10 Aug 2023, 3:18PM Themis Medicare - Quaterly Results10 Aug 2023, 3:18PM Themis Medicare - Quaterly Results10 Aug 2023, 3:18PM Themis Medicare informs about loss of share certificate26 Jun 2023, 11:59AM Themis Medicare informs about investors’ presentation15 May 2023, 10:51AM Themis Medicare - Quaterly Results13 May 2023, 4:15PM Themis Medicare - Quaterly Results13 May 2023, 4:15PM Themis Medicare - Quaterly Results13 May 2023, 4:15PM Themis Medicare informs about compliance certificate17 Apr 2023, 4:03PM Themis Medicare informs about press release 17 Feb 2023, 3:31PM Themis Medicare gets DCGI’s nod to import, market Remifentanil 1mg/2mg Powder for Injection17 Feb 2023, 2:58PM Themis Medicare informs about analyst meet 17 Feb 2023, 10:33AM Themis Medicare informs about loss of share certificate9 Feb 2023, 5:14PM Themis Medicare - Quaterly Results3 Feb 2023, 1:44PM Themis Medicare - Quaterly Results3 Feb 2023, 1:44PM Themis Medicare - Quaterly Results3 Feb 2023, 1:44PM Themis Medicare informs about loss of share certificate2 Feb 2023, 2:52PM Themis Medicare informs about certificate11 Jan 2023, 3:11PM Themis Medicare launches novel transdermal Estradiol spray Lenzetto in Indian market4 Jan 2023, 9:35AM Themis Medicare informs about loss of share certificate28 Dec 2022, 3:24PM Themis Medicare informs about closure of trading window26 Dec 2022, 5:25PM Themis Medicare informs about cancellation of analyst meet 19 Dec 2022, 12:26PM Themis Medicare informs about newspaper publication 13 Dec 2022, 9:54AM Themis Medicare informs about notice of postal ballot and e-voting9 Dec 2022, 4:06PM Themis Medicare informs about transcript of conference call 21 Nov 2022, 4:58PM

Themis Medicare Stock Price Analysis and Quick Research Report. Is Themis Medicare an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Themis Medicare and its performance over the period of time. Themis Medicare stock price today is Rs 261.2.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Themis Medicare cash from the operating activity was Rs 22.0443 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Themis Medicare has a Debt to Equity ratio of 0.318 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Themis Medicare , the EPS growth was -42.8483 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Themis Medicare has OPM of 13.4988977391078 % which is a bad sign for profitability.
     
  • ROE: Themis Medicare have a poor ROE of 8.489 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Themis Medicare is Rs 261.2. One can use valuation calculators of ticker to know if Themis Medicare share price is undervalued or overvalued.
Last Updated on:
Brief about Themis Medicare
X